HealthDay News — The quadrivalent human papillomavirus vaccine appears to be cost-effective for the prevention of oropharyngeal cancer among male patients aged 12 years, according to a study published in Cancer.
“The quadrivalent HPV vaccine (HPV4) has proven efficacy against additional HPV-related disease in both sexes, but the cost effectiveness of male HPV vaccination remains controversial,” noted Donna M. Graham, MB, BCh, of the Princess Margaret Cancer Center in Toronto, and colleagues.
To examine the cost-effectiveness of male HPV vaccination in respect to oropharyngeal cancer (OPC), the scientists performed a preliminary cost-effectiveness analysis. Health-care costs and clinical effectiveness were obtained from an extensive literature review. The potential costs and effectiveness of HPV4 vaccination versus no vaccination were compared in a theoretical cohort based on a Canadian population of 192,940 boys aged 12 years in 2012.
HPV4 produced 0.05 more quality-adjusted life-years (QALYs) and saved $145 (Canadian) per individual compared with no vaccine, assuming 99% vaccine efficacy and 70% uptake. HPV produced 0.023 more QALYs and saved $42 per individual assuming 50% vaccine efficacy and 50% uptake. For the theoretical cohort of 192,940 males, the results indicated that HPV4 may potentially save between $8 and $28 million over the lifetime of the cohort.
“On the basis of this model, HPV vaccination for boys aged 12 years may be a cost-effective strategy for the prevention of OPC in Canada,” concluded the scientists.